Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Racura Oncology Ltd, an ASX-listed oncology-focused biotechnology company, has expanded its equity base through the issuance of additional ordinary fully paid shares. The company continues to use its listed share capital structure to fund and support its cancer therapy development pipeline and maintain engagement with public market investors.
The company has applied for quotation of 1,401,581 new ordinary fully paid shares on the ASX, with an issue date of 7 May 2026. This incremental listing of securities modestly increases the firm’s free float and may enhance liquidity in RAC shares, while providing additional capital flexibility to advance its strategic and operational objectives.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australia-listed biotechnology company focused on developing oncology therapies. The company’s shares trade on the ASX under the ticker RAC, and it issues ordinary fully paid securities as its primary equity instrument for investors seeking exposure to its cancer-focused research and development activities.
Average Trading Volume: 198,668
Technical Sentiment Signal: Buy
Current Market Cap: A$484.7M
Learn more about RAC stock on TipRanks’ Stock Analysis page.